idelalisib
4 abstracts
Abstract
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).Org: Beigene Netherlands B.V., The Alfred and Monash University,
Abstract
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Stanford University Medical Center, Stanford, CA,
Abstract
Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.Org: VA Salt Lake City Health Care, AbbVie Inc., North Chicago, IL, Hunstman Cancer Institute at the University of Utah,
Abstract
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Department of Hematology and Cancer Prevention, Medical University of Silesia, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Memorial Sloan Kettering Cancer Center,